Product Description
GSK2647544 is an inhibitor of lipoprotein-associated phospholipase A2.
Mechanisms of Action: PLA2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GSK
Company Location: Europe
Company CEO: Emma Walmsley
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01978327 |
NCT01978327 | P1 |
Terminated |
Alzheimer Disease |
2014-03-03 |
2019-03-20 |
Treatments |
|
NCT01924858 |
NCT01924858 | P1 |
Terminated |
Alzheimer Disease |
2014-03-03 |
2019-03-19 |
Treatments |
|
NCT01702467 |
NCT01702467 | P1 |
Completed |
Alzheimer Disease |
2013-05-15 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|